Erlotinib-Related Spontaneous Pneumothorax in Patient with Primary Lung Cancer.
10.4046/trd.2010.69.6.465
- Author:
Hae Seong NAM
1
;
Hyeon Jeong LEE
;
Min Su KIM
;
Sung Wook PARK
;
Sang Hoon JEON
;
Jae Hwa CHO
;
Seung Min KWAK
;
Hong Lyeol LEE
;
Jeong Seon RYU
Author Information
1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Korea. jsryu@inha.ac.kr
- Publication Type:Case Report
- Keywords:
Pneumothorax;
Lung neoplasm;
erlotinib
- MeSH:
Accounting;
Adenocarcinoma;
Disease Progression;
Humans;
Korea;
Lung;
Lung Neoplasms;
Pneumothorax;
Quinazolines;
Erlotinib Hydrochloride
- From:Tuberculosis and Respiratory Diseases
2010;69(6):465-468
- CountryRepublic of Korea
- Language:English
-
Abstract:
Spontaneous pneumothorax (SPTx) associated with primary lung cancer is quite rare, but has been reported as the initial presentation or a complication of disease progression. Moreover, chemotherapy-related SPTx in primary lung cancer occurs at a very low frequency, accounting for less than 0.05% of all cases. Here, we report the first case of erlotinib-related SPTx in a patient with advanced lung adenocarcinoma in Korea. After 3 cycles of cisplatin-based chemotherapy as first-line therapy, erlotinib was administered as second-line treatment. Asymptomatic SPTx accompanied by a significant decrease in tumor size was observed in the left lung 7 weeks later. The patient received continuous administration of erlotinib, without additional treatment. This case showed that SPTx can occur in patients with primary lung cancer receiving erlotinib, and asymptomatic chemotherapy-related SPTx in primary lung cancer may not require therapeutic intervention.
